Insurize 60mg Tablet XR contains Gliclazide, a sulfonylurea class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. This extended-release formulation provides a controlled and sustained release of the active ingredient, facilitating once-daily dosing and improving patient adherence. Gliclazide acts primarily by stimulating pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. It also exhibits extrapancreatic effects, including improved peripheral glucose uptake and decreased hepatic glucose production. Insurize 60mg XR is indicated as an adjunct to diet and exercise for glycemic control in patients with type 2 diabetes inadequately controlled by lifestyle modifications alone. It is particularly beneficial in patients with residual pancreatic function. The extended-release mechanism allows for a more stable plasma concentration, minimizing the risk of hypoglycemia compared to immediate-release formulations. Dosage should be individualized based on glycemic response, renal function, and patient tolerance. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and dermatological reactions. Caution is advised in patients with hepatic or renal impairment. Regular monitoring of blood glucose and HbA1c levels is recommended to optimize therapeutic outcomes and minimize complications associated with diabetes.